[
  {
    "text": "(c)immediately upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an",
    "bbox": [
      248,
      72,
      1000,
      86
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "assignment of a substantial portion of the assets for the benefit of creditors by the other Party; provided, however, that",
    "bbox": [
      314,
      89,
      1000,
      102
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if the Party",
    "bbox": [
      313,
      104,
      1000,
      118
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "consents to the involuntary bankruptcy; or.",
    "bbox": [
      314,
      121,
      642,
      133
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "(d)immediately upon notice to the other Party, if such Party (the \"Violating Party\") is convicted of violating any Applicable Law.",
    "bbox": [
      248,
      137,
      1000,
      149
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "including applicable anti-corruption laws, bribery and corruption of public officials as well as private persons and",
    "bbox": [
      314,
      153,
      1000,
      165
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "entities, in connection with its activities under this Agreement and such violation materially adversely affects the ability",
    "bbox": [
      315,
      168,
      1000,
      181
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "remedies as provided by law..",
    "bbox": [
      314,
      201,
      532,
      213
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "8.4Termination Without Cause. After the date that is eighteen (18) months after the Effective Date, either Party may terminate this",
    "bbox": [
      179,
      216,
      1000,
      229
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Agreement upon six (6) months prior written notice to the other Party..",
    "bbox": [
      248,
      233,
      767,
      245
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "8.5Mutual Termination. This Agreement may be terminated at any time by mutual written consent of the Parties.",
    "bbox": [
      179,
      249,
      1000,
      261
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "8.6Termination for Change of Control. This Agreement may be terminated by either Party upon six (6) months written notice following a",
    "bbox": [
      179,
      264,
      1000,
      277
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Change of Control of Exact; provided that such notice is given within thirty (30) days of the consummation of such Change of",
    "bbox": [
      247,
      280,
      1000,
      293
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Control.",
    "bbox": [
      247,
      296,
      309,
      308
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "based on cumulative Incremental Laboratory Services Revenue achieved during the Term or up to the termination date, Exact",
    "bbox": [
      247,
      329,
      1000,
      339
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "agrees to pay Pfizer the applicable royalty payment set forth below for twelve (12) consecutive Calendar Quarters following the.",
    "bbox": [
      247,
      343,
      1000,
      358
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "expiration of the Term (the \"Tail Period'); provided, however, the Tail Period shall be reduced to the number of full Calendar",
    "bbox": [
      247,
      360,
      1000,
      373
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Quarters completed during the Term if less than twelve (12) Calendar Quarters if either Party terminates the Agreement without",
    "bbox": [
      248,
      377,
      1000,
      389
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "cause pursuant to Section 8.4 or Exact terminates as a result of a Change of Control pursuant to Section 8.6. Such royalty",
    "bbox": [
      247,
      393,
      1000,
      405
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "payment shall be payable to Pfizer within thirty (30) days of the end of each Calendar Quarter. Royalty payments shall be",
    "bbox": [
      247,
      409,
      1000,
      421
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "determined by multiplying the Laboratory Services Revenue and the applicable royalty rate from the chart below.",
    "bbox": [
      248,
      425,
      1000,
      437
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Cumulative Incremental Laboratory",
    "bbox": [
      463,
      440,
      731,
      452
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Services Revenue during the Term",
    "bbox": [
      471,
      453,
      725,
      465
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Applicable Royalty Rate.",
    "bbox": [
      991,
      453,
      1000,
      465
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "If< $200 million",
    "bbox": [
      251,
      467,
      368,
      479
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "0%",
    "bbox": [
      1000,
      465,
      1000,
      480
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1%",
    "bbox": [
      1000,
      482,
      1000,
      496
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "If > $200 million and < $400 million",
    "bbox": [
      252,
      485,
      506,
      494
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "If > $400 million and < $600 million",
    "bbox": [
      252,
      500,
      508,
      510
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "2%",
    "bbox": [
      1000,
      499,
      1000,
      511
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "If > $600 million",
    "bbox": [
      252,
      516,
      368,
      527
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "3%",
    "bbox": [
      1000,
      514,
      1000,
      528
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "49",
    "bbox": [
      656,
      531,
      675,
      543
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  }
]